Hutchison China MediTech (HCM) Initiates Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma
Tweet Send to a Friend
Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq: HCM) has initiated a Phase I clinical trial of HMPL-689 in China. HMPL-689 is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
